Prostamax (20 mg Vial) Dosage Protocol
Prostamax is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro / KEDP) derived from prostate tissue peptide complex research. Short peptides of this class are studied for their ability to modulate gene expression through epigenetic interactions with chromatin and histones.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (2 mL = 10 mg/mL)
Route: Intramuscular (IM) injection once daily
| Phase / Week | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 units (0.05 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 9–12 (optional extension) | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
Frequency: Inject once daily intramuscularly. Preclinical studies used daily IM administration for 15–60 days. For administrations ≤10 units (≤0.10 mL), consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; follow product-specific use-by instructions.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (Prostamax, 20 mg each) | 8 weeks ≈ 2 vials (~40 mg total at ~0.7 mg/day average) 12 weeks ≈ 3 vials (~60 mg total) 16 weeks ≈ 4 vials (~80 mg total at ~1 mg/day maintenance) |
| Insulin Syringes (U‑100, 30‑ or 50‑unit recommended for precision) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle 12 weeks (3 vials): 6 mL → 1 × 10 mL bottle 16 weeks (4 vials): 8 mL → 1 × 10 mL bottle |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes |
Protocol Overview
The hypothesized gene-expression mechanism produces effects that persist months after the cycle ends, supporting the cycled rather than continuous approach.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
Prostamax (KEDP) belongs to the class of short bioregulatory peptides studied by Khavinson and colleagues. These tetrapeptides are proposed to modulate gene expression through epigenetic mechanisms, interacting with chromatin structure and histone proteins. In aged human lymphocytes, KEDP has been observed to cause pericentromeric chromatin decondensation, potentially reactivating suppressed genes. Preclinical rat models of prostatitis showed that IM administration of KEDP reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue.
Potential Benefits & Side Effects
Potential Benefits
- Reduced inflammation in rat prostatitis models (IM, 15–60 day treatment).
- Favorable effects on prostate weight and histology in BPH models.
- Short bioregulatory peptides of this class show favorable tolerability in preclinical work.
Side Effect Profile
- Generally well-tolerated in preclinical studies; no published human trials.
- Mild injection-site reactions (redness, tenderness) possible with IM administration.
Lifestyle Factors
- Maintain balanced diet rich in vegetables, healthy fats, and adequate protein.
- Regular physical activity supports circulation and prostate health.
- Adequate hydration; limit alcohol/caffeine may support urinary function.
- Prioritize sleep and stress management.
Injection Technique
- Intramuscular into large muscle group (deltoid, vastus lateralis, or gluteus); 22–25 gauge, 1–1.5 inch needle at 90°.
- Aspiration before IM injection is no longer routinely recommended for most sites.
- Rotate sites systematically to avoid muscle irritation or fibrosis.
- Subcutaneous alternative: 23–25 gauge 5/8 inch needle at 45° into fatty tissue.